Coya Therapeutics, Inc. (COYA)
| Market Cap | 116.35M +10.8% |
| Revenue (ttm) | 7.94M +115.4% |
| Net Income | -21.13M |
| EPS | -1.16 |
| Shares Out | 23.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,043 |
| Open | 5.340 |
| Previous Close | 5.260 |
| Day's Range | 4.900 - 5.340 |
| 52-Week Range | 3.710 - 7.750 |
| Beta | 0.55 |
| Analysts | Strong Buy |
| Price Target | 15.80 (+218.55%) |
| Earnings Date | May 12, 2026 |
About COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatm... [Read more]
Financial Performance
In 2025, Coya Therapeutics's revenue was $7.95 million, an increase of 123.57% compared to the previous year's $3.55 million. Losses were -$21.23 million, 42.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for COYA stock is "Strong Buy." The 12-month stock price target is $15.8, which is an increase of 218.55% from the latest price.
News
Coya Therapeutics granted FDA Fast Track Designation for COYA 302
Coya Therapeutics (COYA) announced that the U.S. Food and Drug Administration has granted Fast Track Designation for COYA 302, a proprietary investigational biologic combination therapy with a dual me...
Coya Therapeutics reports Q1 EPS (32c), consensus (39c)
Reports Q1 revenue $251,147, consensus $71,670. “We are off to a strong start in 2026, building on the clinical and scientific progress achieved last year,” said Arun Swaminathan, Ph.D., Chief…
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg)...
Coya Therapeutics announces publication of research on COYA 302
Coya Therapeutics (COYA) announces the publication of a research study led by Dr. David Beers and Dr. Stanley Appel at the Houston Methodist Neurological Institute. The study included the longitudinal...
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the...
Coya Therapeutics Executive Chairman Howard Berman steps down
Coya Therapeutics (COYA) announced that founder Howard Berman has stepped down as Executive Chairman and as a member of the Board, and that Mark Pavao has been appointed to the…
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya publishes study showing reduction in regulatory T cell function in FTD
Coya Therapeutics (COYA) announced the publication of a research study at the Houston Methodist Neurological Institute, demonstrating the involvement of the peripheral immune system in the neuroinflam...
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the...
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics Transcript: Status update
Targeted combination therapy with low-dose IL-2 and CTLA-4 Ig shows promise in slowing ALS progression, supported by early clinical and biomarker data. The ALSTARS phase II trial aims to confirm efficacy and safety in a larger patient group, with potential for regulatory approval if successful.
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement
Coya Therapeutics (COYA) announced that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2.522M shares of its common stock in…
Coya Therapeutics Announces $11.1 Million Private Placement
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg)...
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the ...
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg)...
Coya Therapeutics announces FDA acceptance of COYA 302 IND application
Coya Therapeutics (COYA) announced that the FDA has accepted the company’s investigational new drug application for COYA 302 for the treatment of frontotemporal dementia.
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg)...
Coya announces Health Canada acceptance of COYA 302 clinical trial application
Coya Therapeutics (COYA) announced that Health Canada has accepted, without objection, the clinical trial application for COYA 302 for the treatment of amyotrophic lateral sclerosis. The CTA acceptanc...
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg)...
Coya Therapeutics commences dosing in ALSTARS trial
Coya Therapeutics (COYA) announced that dosing of ALS patients in the company’s ALSTARS trial of COYA 302 has commenced.
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg)...
Coya Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Significant progress was made in 2025, including advancing the lead asset into a registration-enabling trial, promising data in FTD, and a major licensing deal. The focus remains on ALS and FTD, with plans for new trials and strategic partnerships to expand into larger indications.
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg)...